関連する実験動画
Updated: Sep 10, 2025

06:14
Translational Rabbit Model of Chronic Cardiac Pacing
Published on: January 6, 2023
2.7K
末期性腎疾患の患者における無鉛対静脈ペースメーカー: 系統的レビューとメタ解析
Ștefan Bogdan1,2,3, Mircea Ioan Alexandru Bistriceanu1, Cosmin Gabriel Ursu1
1Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Biomedicines
|August 28, 2025
まとめ
末期腎疾患 (ESRD) の患者における無鉛ペースメーカー (LPM) は,経静脈ペースメーカー (TVP) と比較して,全体的な合併症や早期死亡率を低下させなかった. LPMは,アクセスサイト,血栓,呼吸道合併症の高リスクと関連していました.
科学分野:
- 心臓病科
- 腎臓科
- 医療機器
背景:
- 末期腎疾患 (ESRD) の患者は,ペースメーカーの移植後のデバイス関連の合併症のリスクが高まります.
- 無鉛ペースメーカー (LPM) は潜在的利点がありますが,ESRD患者における安全性と有効性は徹底的な評価を必要とします.
- 静脈経由のペースメーカー (TVP) は従来の標準であり,この集団では独自のリスクを持っています.
研究 の 目的:
- ESRD患者におけるLPMとTVPの臨床結果と合併症プロフィールを比較する.
- 高リスクの患者群でTVPの代替としてLPMの安全性と有効性を評価する.
- ESRD患者のペースメーカーの選択を最適化するためのデータ主導の洞察を提供すること.
主な方法:
- PRISMAのガイドラインに沿った 体系的なレビューとメタ分析
- ESRD患者におけるLPMとTVPを比較した3つの遡及研究が含まれています.
- 主要エンドポイント (全体的な合併症) と,早期死亡率,アクセスサイト合併症,デバイス関連のイベント,血栓性イベント,呼吸器合併症を含む二次結果の分析.
主要な成果:
- LPMとTVPのグループでは,全体的な合併症や早期死亡率に有意な差はありません.
- LPMは,アクセスサイト合併症 (OR2. 51),血栓性イベント (OR1. 42),呼吸器合併症 (OR1. 43) の有意な増加と関連していました.
- この2種類のペースメーカーの間では,デバイスに関連する合併症の割合は比較可能でした.
結論:
- ESRD患者では,LPMはTVPと比較して,全体的な合併症や短期的な死亡率を減少させません.
- LPMは,この集団における特定の手続合併症の高リスクと関連しています.
- 結果は,ESRD患者のペースメーカーに対する臨床的決定を導くために,個別化されたデバイスの選択とさらなる前向きな研究が必要であることを示唆しています.
関連する概念動画
Kidney Transplant I: Introduction
60
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
60
Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152
Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Continuous Renal Replacement Therapy
129
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
129
Renal Drug Clearance: Overview
325
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
325

